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false-positive screening in breast cancer and lung cancer.
However, several new lung-speciﬁc items were needed to obtain
high content coverage and, consequently, make the COS-LC
relevant to lung cancer screening. The questionnaire is currently
in use in the Danish randomised study and will be validated using
Item Response Theory (the Rasch model).
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WHAT CHOICES DO MEN FEELTHEY HAVE IN SELECTION
OF PROSTATE CANCERTREATMENT?
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OBJECTIVES: The purpose is to prospectively describe factors
that may inﬂuence the choice between surgery, radiation, and
watchful waiting among men newly diagnosed with local stage
prostate cancer. METHODS: Beginning in December 2005, pros-
tate cancer patients were approached shortly after diagnosis at
urology clinics in Texas, California and South Carolina. Patients
took home a self-administered survey to complete as they made
their treatment decision. Preliminary data are available for 148
men with recruitment continuing through 2007. Logistic regres-
sion was used to identify factors associated with choice of treat-
ment. RESULTS: Overall 65% of men returned the survey before
starting treatment. A total of 82% indicated they were only
considering (or had considered) a single option; 64% were only
considering surgery, 9% were only considering radiation, 9%
were only considering non-curative therapies, and 18% were
considering multiple options or were unsure of their decision.
Being married (OR 4.7; 95% CI: 1.1, 19.4), being under age 70
(OR 2.7; 95% CI: 1.0, 7.0), and having an annual household
income higher than $60,000 (OR 2.9; 95% CI: 1.0, 8.1) were
strongly associated with considering surgery only. CONCLU-
SION: Understanding why most men feel their only option is
surgery is a priority to ensure that physician biases, patient
misperceptions, or fear do not lead patients to select procedures
that do not agree with their personal preferences. Many patients
appear to make rapid treatment decisions. Interventions to aid
treatment decision-making must target men soon after they
receive their diagnosis.
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OBJECTIVES: To measure and compare preferences for
attributes of colorectal cancer (CRC) screening tests using a
stated preference survey of the general population and physicians
in Canada and the United States (US). METHODS: A stated
preference survey was administered online with 11 choice tasks
between two hypothetical CRC screening tests. Each test was
described by nine attributes: process, pain, preparation, fre-
quency, follow-up, complication risk, sensitivity, speciﬁcity, and
out-of-pocket cost. Each scenario included a follow-up opt-out
question to choose no screening. A total of 1087 US and
501 Canadian respondents participated and 100 physicians
responded in both countries. Physicians were asked to indicate
their patients’ preferences. Responses were modeled using bivari-
ate regression with main effects and interactions with the optout
term. Willingness-to-pay was calculated for common CRC
screening tests. RESULTS: Physicians expected patients to choose
the option of ’no screening’ more frequently than patients them-
selves (55% vs 29% respectively, p < 0.001). For all groups the
most important attribute was sensitivity, but physicians’ percep-
tion of patients’ preferences were signiﬁcantly different from
actual patient preferences. Other key attributes were those
related to test performance or the testing process. Fecal DNA,
colonoscopy, and virtual colonoscopy were the most preferred
tests by all groups, but respondents were willing-to-pay more
than physicians predicted. CONCLUSION: Physicians’ percep-
tion of patients’ preferences are signiﬁcantly different from those
of the general population, although both preferred tests with
high sensitivity. The signiﬁcant difference in the frequency of
choosing no screening between physicians and their patients may
have serious implications for CRC screening uptake since physi-
cians generally exert a strong inﬂuence on decisions about health
care treatment, and especially screening programs. Among
general population and physicians, Canadian and US respon-
dents’ preferences were similar.
EYE—Clinical Outcomes Studies
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OBJECTIVES: Intra-ocular pressure (IOP) ﬂuctuation over 24
hours is an independent risk factor for glaucoma progression.
Night-time IOP measurement is not a routine practice. The aim
of this study was to predict the risk of a nocturnal IOP peak from
day-time measurements. METHODS: IOP measurements from
three clinical trials were pooled. The night-time IOP peak was
deﬁned as the maximum value observed between 00:00 h and
04:00 h. IOP measurements at 08:00 h, 12:00 h, 16:00 h, and
20:00 h were dichotomized using four thresholds: 15, 18, 21,
and 25 mmHg. Patient IOPs were assessed during pre-treatment
washout periods and after treatment with a prostaglandin ana-
logue (PGA: latanoprost or travoprost). A Bayesian network
(BN), adjusted for trial effects, was constructed to study the
association between day-time IOP, nocturnal IOP, and treatment
effects at each of the four thresholds. RESULTS: In total, 382
daily IOP vectors were identiﬁed (pre-treatment: 208; PGA: 174).
The BN association structures differed according to threshold
value. A direct drug effect on the night peak associated with IOP
control at 12:00 was required for a 15 mmHg night IOP target.
Control of IOP at 12:00 and 20:00 was associated with night
control for an 18 mmHg target, at 8:00 and 20:00 for 21 and
25 mmHg targets. Both PGAs were effective in controlling night-
time IOP after it was controlled during the day. Night-time IOP
responder rate differences (pre-treatment minus treatment) pre-
dicted by the BN were 28.7% for the 15 mmHg target, 44.9%
for the 18 mmHg target, 54.0% for the 21 mmHg target, and
9.4% for the 25 mmHg target. CONCLUSION: Day-time IOP
measurements are highly inter-correlated and BNs can help to
predict nocturnal IOP control from day-time measurements. BN
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structures vary by IOP threshold values. Day-time IOP control
with PGAs is associated with night-time IOP control whatever
the IOP threshold.
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INTRA-OCULAR PRESSURE CONTROL OF XALACOM ®
(FIXED LATANOPROST ANDTIMOLOL COMBINATION) AND
DUOTRAV ® (FIXEDTRAVOPROST ANDTIMOLOL
COMBINATION) IN DAILY PRACTICE
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OBJECTIVES: To conﬁrm, in everyday practice, results from
randomized clinical trials indicating that DuoTrav (a ﬁxed tra-
voprost and timolol combination) controls intra-ocular pressure
(IOP) better than Xalacom (a ﬁxed latanoprost and timolol com-
bination), even when measured >24 hours after last instillation.
METHODS: Patients with ocular hypertension or primary open
angle glaucoma and treated by one of the above combinations
were included in this cross-sectional study. Demographics,
medical history and previous treatments were abstracted from
medical records. IOP and treatment time were collected during
an ofﬁce visit. Analyses of variance, logistic regressions and pro-
pensity scores were used to adjust for confounding factors.
RESULTS: In total, 328 patients were included, 127 treated with
DuoTrav and 201 with Xalacom. The mean age was 64.6 years
and 51.5% were female. Most (275: 84.6%) had last instilled
treatment the previous day. Treatment groups were comparable
except that Xalacom-treated patients had longer disease and
treatment durations. Overall mean IOPs were 24.9 mmHg at
diagnosis and 21.1 mmHg upon starting the ﬁxed combination
treatment. There was no signiﬁcant difference between the groups
as they started their second line therapy. Duotrav-treated patients
experienced better IOP control (17.1 versus 19.1 mmHg:
p < 0.001). A difference was also noted for patients who missed
their last scheduled treatment (17.2 versus 20.1 mmHg:
p < 0.006). Better IOP control with DuoTrav was further sup-
ported by patients whose last instillation was 9.00–12.00 hours
before IOP measurement (16.5 versus 19.3 mmHg; p < 0.001).
According to the practitioners, 83.1% of the DuoTrav-treated
patients attained their IOP targets, as compared to 51.3% of
Xalacom-treated patients (p < 0.001). All these differences per-
sisted after adjustment for confounding factors. CONCLUSION:
This everyday practice study paralled the published correspond-
ing prostaglandin results of Topouzis and DuBiner, i.e. compared
to Xalacom, IOP control with DuoTrav is better and has a longer
residual effect when measured >24 hours later.
EYE—Cost Studies
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OBJECTIVES: The rationale for this study was to provide data
for the German health care system in order to investigate the
assumption that ranibizumab is a cost-effective option for the
treatment of neovascular AMD. METHODS: We modeled cost-
effectiveness for ranibizumab-treatment of the patient’s “better”
eye based on the development of visual acuity in our phase III
studies (ANCHOR/MARINA) compared to a control group who
received best supportive care (e.g. visual aids, regular check-ups).
In the base-case, we computed 6 treatments per year for 2 years
and used the same patient entry age (77 years) and distribution of
visual acuity of the model population as in our phase III studies.
Utility values came from a study by Brazier et al. Costs and
beneﬁts were discounted annually at 5%. Costs of drugs and
treatment procedures were determined based on German phar-
macy retail prices, the German code book for physicians’ fees
(EBM 2000plus) and German DRGs. We conducted a sensitivity
analysis in order to test the stability of our model assumptions.
Variations of the base-case scenario included e.g. patient age:
50–85 years, visual acuity at start of therapy: btw. > 4.0 and
0.05–0.1 or duration of therapy: 1–3 years. RESULTS: The base-
case scenario yielded the following costs per QALY: 16.882 € for
predominantly classic lesions, 24.766 € for minimally classic
chorioidal neovascularization (CNV) and 26.170 € for occult
CNV. When weighing the costs per QALY according to the
distribution of these lesion types (18%–25%–57%), the mean
costs per QALY for the therapy of wet AMD with ranibizumab
amount to 24.147 €. The treatment was cost-effective even under
adverse conditions, e.g. longer treatment duration, high visual
acuity at start of treatment, high patient age, increased costs per
injection. CONCLUSION: Therapy of neovascular AMD with
ranibizumab is cost-effective for all angiographic subtypes
assuming a realistic variation of model parameters.
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OBJECTIVES: Ganfort is a ﬁxed combination product contain-
ing bimatoprost 0.03% and timolol 0.5% indicated for lowering
IOP of patients with glaucoma or ocular hypertension. Other
ﬁxed combination products such as Xalacom (latanoprost
0.005% and timolol 0.5%) and Duotrav (travoprost 0.004%and
timolol 0.5%) are also available on the market. All products have
the advantage of being more convenient for the patient due to
once-daily administration. Since no head to head studies
compare the three combination products, an indirect comparison
is used based on available clinical data. The purpose was to
investigate the cost-effectiveness of the three ﬁxed combination
therapies in eight European countries. METHODS: A systematic
literature search was conducted in order to identify randomized
clinical trials of Duotrav and Xalacom. Studies were selected
which had reduction in IOP as primary endpoint and which were
comparable with data from randomized controlled trials of
Ganfort with respect to study design, diagnosis and patient popu-
lation, so that an indirect comparison could be conducted. A
decision analytic cost-effectiveness model was constructed. The
cost evaluated was cost of medication and clinical visits to an
ophthalmologist. All drug costs are market prices inclusive of
VAT and visit costs are priced using ofﬁcial tariffs. Patients
discontinuing treatment due to adverse events were assumed to
change therapy and had an extra clinical visit. RESULTS: The
cost-effectiveness analysis showed that the cost per percentage
reduction in IOP was least costly for Ganfort. By using Ganfort
therapy, savings per percentage reduction in IOP ranged from
€0.06 to €0.22 compared to Duotrav and €0.02 to €0.36 com-
pared to Xalacom. CONCLUSION: This analysis concludes that
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